Serum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: the Age, Gene/Environment Susceptibility-Reykjavik Study.

• Published in: JAMA Ophthalmology
• Main Authors: Semba, Richard D, Cotch, Mary Frances, Gudnason, Vilmundur, Eiríksdottir, Gudny, Harris, Tamara B, Sun, Kai, Klein, Ronald, Jonasson, Fridbert, Ferrucci, Luigi, Schaumberg, Debra A
• Other Authors: Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2Division of Epidemiology and Clinical Research, National Eye Institute, Bethesda, Maryland. 3Icelandic Heart Association, Reykjavik, Iceland4Department of Medicine, University of Iceland, Reykjavik, Iceland. 4Icelandic Heart Association, Reykjavik, Iceland. 5Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, Bethesda, Maryland. 6Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison. 7Department of Medicine, University of Iceland, Reykjavik, Iceland7Department of Ophthalmology, Landspitali University Hospital, Reykjavik, Iceland. 8Longitudinal Studies Section, National Institute on Aging, Baltimore, Maryland. 9Moran Center for Translational Medicine, Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Amer Medical Assoc 2014
• Subjects: Aldraðir; Arfgengi; Sjónhimna; Sjónskerðing; Sjón; Age Factors; Aged; 80 and over; Cross-Sectional Studies; Disease Susceptibility; Enzyme-Linked Immunosorbent Assay; Female; Gene-Environment Interaction; Glycosylation End Products; Advanced; Humans; Iceland; Logistic Models; Lysine; Macular Degeneration; Male; Prevalence; Risk Factors; Visual Acuity
• Online Access: http://hdl.handle.net/2336/325593; https://doi.org/10.1001/jamaophthalmol.2013.7664

IMPORTANCE Advanced glycation end products have been implicated in the pathogenesis of age-related macular degeneration (AMD). OBJECTIVE To investigate the relationship between serum carboxymethyllysine (CML), a major circulating advanced glycation end product, and AMD in older adults. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of a population-based sample of 4907 older adults (aged ≥66 years) in the Age, Gene/Environment Susceptibility-Reykjavik Study in Iceland. EXPOSURES Serum CML and risk factors for AMD. MAIN OUTCOMES AND MEASURES Early or late AMD, assessed through fundus images taken through dilated pupils using a 45° digital camera and grading for drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System. RESULTS Of the 4907 participants, 1025 (20.9%) had early AMD and 276 (5.6%) had late AMD. Mean (SD) serum CML concentrations among adults with no AMD, early AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (195.5), 634.2 (206.4), and 638.4 (192.0) ng/mL, respectively (to convert to micromoles per liter, multiply by 0.00489; P = .07). Log serum CML (per 1-SD increase) was not associated with any AMD (early and late AMD) (odds ratio = 0.97; 95% CI, 0.90-1.04; P = .44) or with late AMD (odds ratio = 0.94; 95% CI, 0.82-1.08; P = .36) in respective multivariable logistic regression models adjusting for age, sex, body mass index, smoking, and renal function. CONCLUSIONS AND RELEVANCE Higher serum CML concentration had no significant cross-sectional association with prevalent AMD in this large population-based cohort of older adults in Iceland. National Institutes of Health R01 AG027012 R01 EY017362 Intramural Research Program of the National Eye Institute ZIAEYO0401 Intramural Research Program of the National Institute on Aging NO1-AG-1-2100 Icelandic Heart Association Icelandic Parliament University of Iceland Research Fund ...